Xbrane Biopharma AB ("Xbrane" or the "Company") announces changes to the number of shares and votes in the Company.

Nyheter Xbrane Biopharma Nyheter alla bolag

Courtagefri handel på Nordnet till sista juni 2027! Har du inget konto på Nordnet så är det verkligen läge att skaffa ett. Just nu får nya kunder courtagefri handel till sista juni 2027. Läs mer om erbjudandet och skapa ditt konto här

Erbjudandet gäller nya kunder och omfattar handel via Nordnets app eller hemsida i nordiska aktier, ETF:er, teckningsrätter och teckningsoptioner. För fullständiga villkor se nordnet.se/jubileum. Kom ihåg att investeringar alltid innebär en risk.

Xbrane Biopharma AB ("Xbrane" or the "Company") announces changes to the number of shares and votes in the Company.

LHFI

The number of shares and votes in Xbrane have changed following the issue of 105,000 shares during June through exercise of warrants under LTIP 2019, adopted at the annual general meeting 2019.

As of June 30, 2022, the total number of shares and votes in the Company amounts to 25,144,906. The Company's registered share capital amounts to SEK 5,637,137.439365.

About Us

Xbrane Biopharma AB develops biological drugs based on a patented platform technology that provides significantly lower production costs compared to competing systems. Xbrane has a portfolio of biosimilar candidates targeting SEK 332 billion in annual sales of the respective reference products, with the leading one under registration in Europe. Xbrane’s head office is in Solna, just outside Stockholm. Xbrane is listed on Nasdaq Stockholm under the ticker XBRANE. For more information, visit www.xbrane.com

Datum	2022-06-30, kl 12:00
Källa	MFN

Bifogade filer

Xbrane Biopharma AB ("Xbrane" or the "Company") announces changes to the number of shares and votes in the Company.

LOGGA IN

Xbrane Biopharma

Affiliate

Xbrane Biopharma AB ("Xbrane" or the "Company") announces changes to the number of shares and votes in the Company.